share_log

Entheon Biomedical Announces Non-Brokered Private Placement Financing

Entheon Biomedical Announces Non-Brokered Private Placement Financing

Entheon Biomedical宣佈非經紀私募融資
Benzinga Real-time News ·  2022/04/05 15:46

Entheon Biomedical Corp. (OTCQB:ENTBF) announced a non-brokered private placement financing for up to 30,000,000 Units at a price of CDN$0.10 per unit, for gross proceeds of up to CDN$3,000,000.
Each unit will consist of one common share in the capital of the company and one transferable share purchase warrant. Each warrant will be exercisable to acquire one additional share for a period of 36 months from the date of issue. The exercise price will be CDN$0.15 per share in year one, and CDN$0.25 in the two following years.
According to the company, the goal of the private placement is to finance research and development activities, general working capital and corporate purposes with its proceedings.
Earlier this year, Entheon had announced the approval by Dutch authorities of a Phase 1 clinical trial on DMT.

Entheon Biomedical Corp.(場外交易代碼:ENTBF)宣佈非經紀私募融資以每單位0.10加元的價格購買最多30,000,000個單位,總收益高達300萬加元。
每個單位將包括一股公司股本中的普通股和一份可轉讓的股份認購權證。每份認股權證可於發行日期起計36個月內行使,以增持一股股份。第一年的行權價格將為每股0.15加元,隨後兩年的行權價格為0.25加元。
據該公司稱,私募的目標是為研發活動、一般營運資金和公司目的提供資金。它的訴訟程序。
今年早些時候,Entheon宣佈了荷蘭當局批准了DMT的一期臨牀試驗。

Photo by micheile on Unsplash

米凱爾在Unspash上的照片

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論